Pituitary tumors and the risk of other malignancies: is the relationship coincidental or causal?
- PMID: 37435457
- PMCID: PMC10259320
- DOI: 10.1530/EO-21-0033
Pituitary tumors and the risk of other malignancies: is the relationship coincidental or causal?
Abstract
Pituitary adenomas are benign neoplasms of the pituitary. The most prevalent are prolactinomas and non-functioning pituitary adenomas, followed by growth hormone- and ACTH-secreting adenomas. Most pituitary adenomas seem to be sporadic and their persistent growth is very atypical. No molecular markers predict their behavior. The occurrence of pituitary adenomas and malignancies in the same patient can be either pure coincidence or caused by shared underlying genetic susceptibility involved in tumorigenesis. Detailed family history on cancers/tumors in the first, second and third generation of family members on each side of the family has been reported in a few studies. They found an association of pituitary tumors with positive family history for breast, lung and colorectal cancer. We have reported that in about 50% of patients with pituitary adenomas, an association with positive family history for cancer has been found independent of secretory phenotype (acromegaly, prolactinoma, Cushing's disease or non-functioning pituitary adenomas). We also found earlier onset of pituitary tumors (younger age at diagnosis of pituitary tumors) in patients with a strong family history of cancer. In our recent unpublished series of 1300 patients with pituitary adenomas, 6.8% of patients were diagnosed with malignancy. The latency period between the diagnosis of pituitary adenoma and cancer was variable, and in 33% of patients, it was longer than 5 years. Besides the inherited trophic mechanisms (shared underlying genetic variants), the potential influence of shared complex epigenetic influences (environmental and behavioral factors - obesity, smoking, alcohol intake and insulin resistance) is discussed. Further studies are needed to better understand if patients with pituitary adenomas are at increased risk for cancer.
Keywords: endocrine disruptor; family history; malignancy; pituitary tumor.
© The authors.
Conflict of interest statement
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.
Similar articles
-
Familial Cancer Clustering in Patients with Prolactinoma.Horm Cancer. 2019 Feb;10(1):45-50. doi: 10.1007/s12672-018-0348-3. Epub 2018 Sep 8. Horm Cancer. 2019. PMID: 30196424 Free PMC article.
-
[Clinically active pituitary tumors].Inn Med (Heidelb). 2024 Jul;65(7):672-680. doi: 10.1007/s00108-024-01729-9. Epub 2024 Jun 13. Inn Med (Heidelb). 2024. PMID: 38869654 Review. German.
-
Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients.J Clin Endocrinol Metab. 2012 Apr;97(4):E663-70. doi: 10.1210/jc.2011-2291. Epub 2012 Feb 8. J Clin Endocrinol Metab. 2012. PMID: 22319033
-
Radiation therapy in the multimodal treatment approach of pituitary adenoma.Strahlenther Onkol. 2002 Apr;178(4):173-86. doi: 10.1007/s00066-002-0826-x. Strahlenther Onkol. 2002. PMID: 12040754 Review.
-
Hormone secretion by pituitary adenomas is characterized by increased disorderliness and spikiness but more regular pulsing.J Clin Endocrinol Metab. 2014 Oct;99(10):3836-44. doi: 10.1210/jc.2014-2363. Epub 2014 Jul 11. J Clin Endocrinol Metab. 2014. PMID: 25014002 Free PMC article.
Cited by
-
Increased Prevalence of Germline Pathogenic CHEK2 Variants in Individuals With Pituitary Adenomas.J Clin Endocrinol Metab. 2024 Oct 15;109(11):2720-2728. doi: 10.1210/clinem/dgae268. J Clin Endocrinol Metab. 2024. PMID: 38651569 Free PMC article.
-
Beyond Occam's Razor: Concurrent Non-functional Pituitary Macroadenoma and Metastatic Hepatocellular Carcinoma in a Patient With Functional Cure of Hepatitis B.Cureus. 2024 Jun 13;16(6):e62339. doi: 10.7759/cureus.62339. eCollection 2024 Jun. Cureus. 2024. PMID: 39006628 Free PMC article.
-
Impact of Heavy Metals on Glioma Tumorigenesis.Int J Mol Sci. 2023 Oct 21;24(20):15432. doi: 10.3390/ijms242015432. Int J Mol Sci. 2023. PMID: 37895109 Free PMC article. Review.
-
Editorial: Cancer risk in patients with acromegaly - is extensive screening needed?Front Endocrinol (Lausanne). 2024 Oct 28;15:1503633. doi: 10.3389/fendo.2024.1503633. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39534256 Free PMC article. No abstract available.
References
-
- Aguiar-Oliveira MH, Oliveira FT, Pereira RM, Oliveira CR, Blackford A, Valenca EH, Santos EG, Gois-Junior MB, Meneguz Moreno RA, Araujo VPet al.2010Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene. Journal of Clinical Endocrinology and Metabolism 95714–721. (10.1210/jc.2009-1879) - DOI - PMC - PubMed
-
- Albertelli M, Nazzari E, Dotto A, Grasso LF, Sciallero S, Pirchio R, Rebora A, Boschetti M, Pivonello R, Ricci Bitti Set al.2021Possible protective role of metformin therapy on colonic polyps in acromegaly: an exploratory cross-sectional study. European Journal of Endocrinology 184419–425. (10.1530/EJE-20-0795) - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources